Shree Ganesh Biotech Reports Strong Sales Growth Amid Liquidity Challenges for Q4 2024

Shree Ganesh Biotech India has recently reported its financial results for the quarter ending December 2024, showcasing notable developments in its performance metrics. The company, operating within the agriculture sector, has experienced a significant adjustment in its evaluation, with its score reflecting a positive shift from -7 to 17 over the past three months.
The financial results indicate a robust growth trajectory, particularly in net sales, which reached Rs 16.39 crore, marking a year-on-year increase of 98.91%. This figure surpasses the previous twelve-month period's sales of Rs 15.58 crore, highlighting a strong sales trend. Additionally, the company reported its highest operating profit, profit before tax, and profit after tax in the last five quarters, all at Rs 0.47 crore and Rs 0.77 crore respectively, suggesting a favorable near-term outlook for profitability.

However, challenges remain, particularly in liquidity, as cash and cash equivalents have reached a low of Rs 0.01 crore, and the debtors turnover ratio has declined to 0.00 times, indicating a slowdown in the company's ability to settle its debts.

For further insights into Shree Ganesh Biotech India's financial trends and performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.